Table 3 Comparison of positive immunohistochemical staining correlated to molecular alterations
| Â | ANXA10 positive | MUC5AC positive | MUC6 positive | CDX2 high expression | ||||
|---|---|---|---|---|---|---|---|---|
| Â | N=36 | P-value | N=67 | P-value | N=41 | P-value | N=86 | P-value |
BRAF mutation | Â | <0.0001 | Â | <0.0001 | Â | <0.0001 | Â | <0.0001 |
 Present (n=38) | 27 (75%) |  | 32 (48%) |  | 22 (54%) |  | 16 (19%) |  |
 Absent (n=85) | 9 (25%) |  | 35 (52%) |  | 19 (46%) |  | 70 (81%) |  |
KRAS mutation | Â | 0.016 | Â | 0.24 | Â | 0.022 | Â | 0.048 |
 Present (n=23) | 2 (6%) |  | 10 (15%) |  | 3 (7%) |  | 20 (23%) |  |
 Absent (n=100) | 34 (94%) |  | 57 (85%) |  | 38 (93%) |  | 66 (77%) |  |
CpG island methylator phenotype | Â | <0.0001 | Â | 0.001 | Â | <0.0001 | Â | <0.0001 |
 Positive (n=46) | 26 (72%) |  | 34 (51%) |  | 28 (68%) |  | 20 (23%) |  |
 Negative (n=77) | 10 (28%) |  | 33 (49%) |  | 13 (32%) |  | 66 (77%) |  |
Microsatellite status | Â | 0.072 | Â | 0.001 | Â | <0.0001 | Â | 0.002 |
 Unstable (n=28) | 12 (33%) |  | 23 (34%) |  | 20 (49%) |  | 13 (15%) |  |
 Stable (n=95) | 24 (67%) |  | 44 (66%) |  | 21 (51%) |  | 73 (85%) |  |
Molecular subgroup of carcinoma | Â | <0.0001 | Â | <0.0001 | Â | <0.0001 | Â | <0.0001 |
 Group 1 (n=18) | 10 (28%) |  | 17 (25%) |  | 16 (39%) |  | 6 (7%) |  |
 Group 2 (n=40) | 24 (67%) |  | 27 (40%) |  | 16 (39%) |  | 23 (27%) |  |
 Group 3 (n=55) | 0 (0%) |  | 17 (25%) |  | 5 (12%) |  | 50 (58%) |  |
 Group 4 (n=10) | 2 (6%) |  | 6 (9%) |  | 4 (10%) |  | 7 (8%) |  |
